Ranolazine treatment for refractory angina in a patient with Hutchinson-Gilford progeria syndrome and end stage aortic stenosis

  • Giuseppe Limongelli Unit of Pediatric Cardiology, Department of Translational Sciences, Luigi Vanvitelli University, AORN Colli, Monaldi Hospital, Naples, Italy; Institute of Cardiovascular Sciences, University College of London, United Kingdom.
  • Emanuele Monda | emanuelemonda@me.com Unit of Pediatric Cardiology, Department of Translational Sciences, Luigi Vanvitelli University, AORN Colli, Monaldi Hospital, Naples, Italy.
  • Giovanbattista Capozzi Unit of Pediatric Cardiology, Department of Translational Sciences, Luigi Vanvitelli University, AORN Colli, Monaldi Hospital, Naples, Italy.
  • Martina Caiazza Unit of Pediatric Cardiology, Department of Translational Sciences, Luigi Vanvitelli University, AORN Colli, Monaldi Hospital, Naples, Italy.
  • Maria Giovanna Russo Unit of Pediatric Cardiology, Department of Translational Sciences, Luigi Vanvitelli University, AORN Colli, Monaldi Hospital, Naples, Italy.

Abstract

Management of symptoms in patients with inoperable aortic stenosis is often hard in clinical practice. We report a case of a patient with Hutchinson-Gilford progeria syndrome and end-stage aortic stenosis, considered not suitable for surgical or percutaneous approach, to whom the administration of ranolazine resulted in a considerable improvement of angina, refractory to other treatments.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-01-30
Info
Issue
Section
Clinical and Experimental Cases/Hypothesis
Keywords:
Hutchinson-Gilford progeria syndrome, aortic stenosis, ranolazine.
Statistics
  • Abstract views: 325

  • PDF: 127
How to Cite
Limongelli, G., Monda, E., Capozzi, G., Caiazza, M., & Russo, M. G. (2020). Ranolazine treatment for refractory angina in a patient with Hutchinson-Gilford progeria syndrome and end stage aortic stenosis. Cardiogenetics, 9(1). https://doi.org/10.4081/cardiogenetics.2019.8609